The company reported a net profit of ₹64.3 crore for for the March quarter, down 41.5% from ₹110 crore in the corresponding quarter last year. Revenue from operations declined 31% year-on-year to ₹235 crore from ₹340 crore earlier.
Earnings Before Interest, Tax, Depreciation and Amortisation (EBITDA) fell 49% to ₹71 crore from ₹140 crore a year ago, while EBITDA margin contracted sharply to 30.3% from 41%.
Profit before tax for the quarter stood at ₹87.1 crore compared to ₹147.2 crore in the year-ago period, while total expenses declined to ₹170.4 crore from ₹205.4 crore.Also read: Park Medi shares jump 8% on ₹177 crore Uttarkhand hospital acquisition
For FY26, Blue Jet Healthcare reported revenue from operations of ₹947.3 crore compared to ₹1,030 crore in FY25, while annual net profit fell to ₹247.8 crore from ₹305.2 crore a year ago. EBITDA for FY26 stood at ₹332.5 crore against ₹406.1 crore in FY25.
The board recommended a final dividend of ₹1.2 per equity share of face value ₹2 each for FY26, subject to shareholder approval.
Separately, the company’s board approved a proposal to raise up to ₹1,000 crore through qualified institutional placements (QIP), preferential issue, private placement or other permissible routes, subject to shareholder and regulatory approvals.
Blue Jet Healthcare also said it will hold an extraordinary general meeting on June 17, 2026, to seek shareholder approval for the proposed fundraise.
Shares of Blue Jet Healthcare are now trading 6.8% higher having gained as much as 10% at ₹471.8. The stock is still down 11% so far in 2026.
